Pharmacological inhibition of DOT1L in cell line and xenograft models of KMT2A-r leukemia has shown anti-leukemic activity and restores normal HOXA and MEIS1 transcription (Daigle et al., 2011, 2013). Here, DOT1L is linked to leukemia.